Stockscreener 앱 받기
64.80
3.37%
-2.26
시장 영업 전:
65.09
0.29
+0.45%
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - MarketBeat
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Federated Hermes Inc. Decreases Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics closes $747.5 million public offering - Investing.com
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by HighVista Strategies LLC - MarketBeat
Structure Therapeutics announces $650 million public offering - MSN
Structure Therapeutics Announces $650 Million Public Offering - TipRanks
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics prices upsized $650 million public offering - Investing.com
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewswire Inc.
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial - Finviz
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Discipline and Rules-Based Execution in GPCR Response - news.stocktradersdaily.com
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook - ts2.tech
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - Yahoo Finance
This trade activity should not be overlooked: Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics stock price target raised to $130 by BMO Capital - Investing.com
Structure Therapeutics stock price target raised to $99 at Clear Street - Investing.com
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More - ts2.tech
Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill - The Wall Street Journal
Why Structure Therapeutics Stock Doubled and Then Some on Monday - The Globe and Mail
Structure Therapeutics stock hits 52-week high at 45.05 USD By Investing.com - Investing.com Canada
Structure Therapeutics Unveils Major Data Release Driving Market Buzz - StocksToTrade
Structure Therapeutics stock price target raised to $90 by Stifel - Investing.com
Structure Therapeutics stock falls after $500 million share offering By Investing.com - Investing.com India
Structure Therapeutics stock falls after $500 million share offering - Investing.com
Structure Therapeutics launches $500 million public offering - Investing.com
Structure Therapeutics launches $500 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics (NASDAQ: GPCR) plans $500M ADS sale with $75M option - Stock Titan
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
Structure Therapeutics’ Potential Breakthrough: Market Awaits Data - StocksToTrade
Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation - TipRanks
Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year HighStill a Buy? - MarketBeat
Structure Phase 2 data for aleniglipron look ‘competitive,’ says Morgan Stanley - TipRanks
Structure Therapeutics posts mid-stage weight-loss pill data in line with Eli Lilly rival - Sherwood News
Structure Therapeutics stock hits 52-week high at 45.05 USD - Investing.com
Structure Therapeutics Announces Positive Clinical Trial Results - TipRanks
Structure Therapeutics stock soars after strong weight loss data for oral drug - Investing.com UK
0.36%
1.05%
자본화:
|
볼륨(24시간):